Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b.
about
Structural and Functional Analysis of a C3b-specific Antibody That Selectively Inhibits the Alternative Pathway of ComplementAntibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factorsExhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patientsComplement consumption in children with Plasmodium falciparum malariaNK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca(2+) influx and induces streamers.Complement, thrombotic microangiopathy and disseminated intravascular coagulation.Identification of C3b-Binding Small-Molecule Complement Inhibitors Using Cheminformatics.Therapeutic control of complement activation at the level of the central component C3.Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy.Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury.Real-time label-free detection of complement activation products in human serum by white light reflectance spectroscopyFunctional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications.Expanding horizons in complement drug discovery: challenges and emerging strategies.Endothelial Microparticles and Systemic Complement Activation in Patients With Chronic Kidney Disease
P2860
Q27653668-28D1CE5C-0516-4B3C-8BD3-B9E69DAF6029Q30276243-69BB6A70-0AA1-4597-91C1-85964AF2E7A3Q30409539-98C8D757-04D0-40A8-983D-DC05E34CA553Q30421637-445D6A95-A6F9-45A3-9954-9F98FDAEFCBFQ30440213-F6BC86A9-A257-4391-A8D9-ACC84FB2BE04Q30440293-C676E85F-8E85-46DA-BD1B-2037C62BD8BDQ30453680-B134FE0E-AB94-4754-BBCD-414F5C58408AQ33420624-18E91C54-73BB-4E3C-987C-6D80B3CB83E0Q36309711-CC8086BF-D2FD-4D45-85F9-ECF840BDE21DQ36363005-037D2921-D701-4A7B-8788-C18EB9B9C691Q36463266-93FE6589-90F5-402D-9339-3EAA71029372Q37017177-9B63A537-6D0D-413A-B19E-15FEE99164C2Q37343678-99EC24FF-6552-4934-8ABB-7D1903A8CACEQ46433084-4C963B6D-EAFE-46E1-ACDA-88137307251FQ49439487-53C697E1-D106-4B16-B679-D84306052764Q56341973-7A5976CE-DE89-4F7A-B560-A3E5BEEB691E
P2860
Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Selective and efficient inhibi ...... mAb that recognizes C3b/iC3b.
@ast
Selective and efficient inhibi ...... mAb that recognizes C3b/iC3b.
@en
type
label
Selective and efficient inhibi ...... mAb that recognizes C3b/iC3b.
@ast
Selective and efficient inhibi ...... mAb that recognizes C3b/iC3b.
@en
prefLabel
Selective and efficient inhibi ...... mAb that recognizes C3b/iC3b.
@ast
Selective and efficient inhibi ...... mAb that recognizes C3b/iC3b.
@en
P2093
P1433
P1476
Selective and efficient inhibi ...... mAb that recognizes C3b/iC3b.
@en
P2093
Adam D Kennedy
Andrew W Pawluczkowycz
David J DiLillo
Margaret A Lindorfer
Paul V Beum
Ronald P Taylor
P304
P356
10.1016/J.MOLIMM.2005.05.003
P577
2005-06-14T00:00:00Z